CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn is a biotech that has been effective faithfully but unsuccessfully to create an one off therapy, variously called Pro 140, leronlimab, as well as Vyrologix.
In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.
CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is actually an open question.
While CYDY is actually dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.
I’m creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last several shares. The first CytoDyn article of mine, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out what follows prediction:
Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire interview which I came away with a bad opinion of the company.
Irony of irony, the poor impression of mine of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.
What manner of stock is it that delivers a > six bagger yet still disappoints? Therein sits the story; permit me to explain.
CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:
CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of this know-how and also connected intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) as well as the first new drug application endorsement ($five million), and also royalty payments of five percent of net sales upon commercialization.
Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to get a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

As opposed to having a pipeline with many indications and many therapies, it’s this single treatments as well as a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy in dozens of indications.
The opening banner of its on the site of its (below) shows an active company with diverse interests albeit centered on leronlimab, multiple illness types, multiple publications in addition to multiple presentations.
Could all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself from the very start of the interest of mine in this organization. Judging by way of the multiples of a huge number of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.
CytoDyn is a traditional battleground, or maybe some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short mongering.
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News